AstraZeneca Expands U.S. Investment Plan
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, and other sites across the West and East Coasts, creating more than 1,000 jobs.
Pharma Giant AstraZeneca Takes China Probes
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of ...
Reports Q3 revenue $13.6B, consensus $13.09B. Pascal Soriot, CEO, AstraZeneca (AZN), commenting on the results said: “Our company has ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00. The company’s shares opened today at p10,290.00. Welford ...
AstraZeneca has upgraded its annual guidance for the second time this year after sales of its cancer drugs soared in the ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback